Sugi Predict

Sugi Predict / Compounds / SCHEMBL2330263

SCHEMBL2330263

SCHEMBL2330263

O=C(CCl)Nc1ccc(-c2ccccc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 1.00
▸ HTT P42858 4/20 1.00
▸ NPC1 O15118 3/20 1.00
▸ RAB9A P51151 3/20 1.00
▸ MITF O75030 3/20 1.00
▸ SMN1; SMN2 Q16637 2/20 1.00
▸ KMT2A Q03164 4/20 0.67
▸ MEN1 O00255 3/20 0.67
▸ LMNA P02545 2/20 0.67
▸ MAPT P10636 2/20 0.67
▸ KDM4E B2RXH2 1/20 0.67
▸ RNF4 P78317 1/20 0.67
▸ OGT O15294 1/20 0.62
▸ XBP1 P17861 1/20 0.59
▸ NPSR1 Q6W5P4 1/20 0.59
▸ NOD2 Q9HC29 1/20 0.59
▸ HDAC3 O15379 3/20 0.58
▸ HDAC4 P56524 3/20 0.58
▸ HDAC1 Q13547 3/20 0.58
▸ HDAC7 Q8WUI4 3/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL44662 0.88 HTT (0.78) ALDH1A1HTTNPC1RAB9AMITF
SCHEMBL8480777 0.86 ALDH1A1 (0.74) ALDH1A1HTTNPC1RAB9AMITF
Ammonia Solution, Strong SCHEMBL27754901 0.86 HTT (0.75) ALDH1A1HTTNPC1RAB9AMITF
Iodide SCHEMBL998878 0.86 HTT (0.75) ALDH1A1HTTNPC1RAB9AMITF
Methane SCHEMBL27966936 0.86 HTT (0.75) ALDH1A1HTTNPC1RAB9AMITF
Hydrochloric Acid SCHEMBL9483678 0.86 HTT (0.75) ALDH1A1HTTNPC1RAB9AMITF
Hydrogen Sulfide SCHEMBL10948577 0.86 HTT (0.75) ALDH1A1HTTNPC1RAB9AMITF
Ammonia Solution, Strong SCHEMBL27422908 0.86 HTT (0.75) ALDH1A1HTTNPC1RAB9AMITF
SCHEMBL9081388 0.85 NPC1 (0.76) ALDH1A1HTTNPC1RAB9AMITF
SCHEMBL11655190 0.85 ALDH1A1 (0.73) ALDH1A1HTTNPC1RAB9AMITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025229046-A1 SUBSTITUTED HYDROQUINOLINES FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME MOLIUS SAGLIK TEKNOLOJILERI ANONIM SIRKETI (TR) 2025-11-06 — — WO disclosed
EP-4644375-A1 SUBSTITUTED HYDROQUINOLINES FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME Molius Saglik Teknolojileri Anonim Sirketi (TR) 2025-11-05 — — EP disclosed
CN-118496159-B Application of compound in preparation of medicine with liver fibrosis preventing and/or treating effect 广州医科大学附属市八医院 2024-09-24 — — CN disclosed
CN-118496159-A Application of compound in preparation of medicine with liver fibrosis preventing and/or treating effect 广州医科大学附属市八医院 2024-08-16 — — CN disclosed
WO-2023125751-A1 DIA-BASED QUANTITATIVE CHEMICAL PROTEOMICS TARGET SCREENING METHOD 北京大学 2023-07-06 — — WO disclosed
US-20220298213-A1 IN VIVO ENGINEERED CEREBLON PROTEIN VIVIDION THERAPEUTICS, INC. 2022-09-22 — — US disclosed
CN-114072000-A Molecules having certain pesticidal effects and intermediates, compositions and methods related thereto 科迪华农业科技有限责任公司 2022-02-18 — — CN disclosed
WO-2021011722-A1 MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO DOW AGROSCIENCES LLC (US) 2021-01-21 — — WO disclosed
US-20210002337-A1 IN VIVO ENGINEERED CEREBLON PROTEIN THE SCRIPPS RESEARCH INSTITUTE 2021-01-07 — — US disclosed
US-10781239-B2 In vivo engineered cereblon protein VIVIDION THERAPEUTICS, INC. (US) 2020-09-22 — — US disclosed
US-9119853-B2 Sanglifehrin based compounds NEUROVIVE PHARMACEUTICAL AB (SE) 2015-09-01 — — US disclosed
US-9119853-B2 Sanglifehrin based compounds NEUROVIVE PHARMACEUTICAL AB (SE) 2015-09-01 — — US disclosed
EP-2533784-B1 SANGLIFEHRIN BASED COMPOUNDS NEUROVIVE PHARMACEUTICAL AB (SE) 2015-04-22 — — EP disclosed
EP-2533784-B1 SANGLIFEHRIN BASED COMPOUNDS NEUROVIVE PHARMACEUTICAL AB (SE) 2015-04-22 — — EP disclosed
EP-2533784-A1 SANGLIFEHRIN BASED COMPOUNDS Biotica Technology Limited (GB) 2012-12-19 — — EP disclosed
US-20120295841-A1 Sanglifehrin Based Compounds Abliva Ab (SE) 2012-11-22 — — US disclosed
US-20120295841-A1 Sanglifehrin Based Compounds Abliva Ab (SE) 2012-11-22 — — US disclosed
US-20120295841-A1 Sanglifehrin Based Compounds Abliva Ab (SE) 2012-11-22 — — US disclosed
WO-2011098809-A1 SANGLIFEHRIN BASED COMPOUNDS BIOTICA TECHNOLOGY LIMITED (GB) 2011-08-18 — — WO disclosed
WO-2011098809-A1 SANGLIFEHRIN BASED COMPOUNDS BIOTICA TECHNOLOGY LIMITED (GB) 2011-08-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220298213-A1 IN VIVO ENGINEERED CEREBLON PROTEIN CRBN, CDR2, DCUN1D4 ALDH1A1 2798/4885HTT 3236/4885NPC1 4139/4885
US-20210002337-A1 IN VIVO ENGINEERED CEREBLON PROTEIN CRBN, CDR2, DCUN1D4 ALDH1A1 2798/4885HTT 3236/4885NPC1 4139/4885
US-20120295841-A1 Sanglifehrin Based Compounds HSP90B1, HSPH1, HSP90AB2P ALDH1A1 3274/4885HTT 2131/4885NPC1 200/4885
US-10781239-B2 In vivo engineered cereblon protein CRBN, CDR2, DCUN1D4 ALDH1A1 2798/4885HTT 3236/4885NPC1 4139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.